Acolbifene/prasterone
Tools
Actions
General
Print/export
In other projects
Appearance
From Wikipedia, the free encyclopedia
Combination formulation of aclobifene and prasterone
Combination of | |
---|---|
Acolbifene | Selective estrogen receptor modulator |
Prasterone | Androgen |
Clinical data | |
Trade names | Femivia (tentative) |
Other names | Prasterone/acolbifene; Acolbifene/DHEA; DHEA/Acolbifene |
Routes of administration | By mouth |
Acolbifene/prasterone (tentative brand name Femivia) is a combination formulation of acolbifene, a selective estrogen receptor modulator, and prasterone (dehydroepiandrosterone; DHEA), an androgen, estrogen, and neurosteroid, which is under development by Endoceutics for the treatment of vasomotor symptoms (hot flashes) in postmenopausal women.[1] It is intended for use by mouth.[1] As of December 2017, it is in phase III clinical trials for this indication.[1]
See also
[edit]References
[edit]External links
[edit]- Acolbifene/prasterone - AdisInsight
- Pipeline - Endoceutics Archived 2017-10-18 at the Wayback Machine
ERTooltip Estrogen receptor |
| ||||||
---|---|---|---|---|---|---|---|
GPERTooltip G protein-coupled estrogen receptor |
| ||||||
This drug article relating to the genito-urinary system is a stub. You can help Wikipedia by expanding it. |
Hidden categories:
- Articles with short description
- Short description matches Wikidata
- Chemical articles without CAS registry number
- Articles without EBI source
- Chemical pages without ChemSpiderID
- Chemical pages without DrugBank identifier
- Articles without KEGG source
- Articles without InChI source
- Articles without UNII source
- Drugs missing an ATC code
- Drugs with no legal status
- Articles containing unverified chemical infoboxes
- Drugs that are a combination of chemicals
- Webarchive template wayback links
- All stub articles